Evaluation of Ascorbate-Meglumine Therapeutic for SRS
Status:
ENROLLING_BY_INVITATION
Trial end date:
2025-09-09
Target enrollment:
Participant gender:
Summary
Phase 1, Single-Center, Dose-Escalating, Open-Label, Safety Clinical Trial of Parenteral Ascorbate-Meglumine as a Novel Magnetic Resonance Imaging (MRI)-guided Adjunctive Therapeutic for Stereotactic Radiosurgery (SRS)